Sugi Predict

Sugi Predict / Compounds / SCHEMBL991333

SCHEMBL991333

SCHEMBL991333

O=C(OOOC(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.80
▸ F2 P00734 1/20 0.80
▸ TSHR P16473 6/20 0.59
▸ ALDH1A1 P00352 4/20 0.59
▸ TDP1 Q9NUW8 4/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ TP53 P04637 1/20 0.52
▸ KMT2A Q03164 3/20 0.50
▸ MAPT P10636 3/20 0.50
▸ CES2 O00748 2/20 0.50
▸ CES1 P23141 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ HIF1A Q16665 1/20 0.50
▸ DAO P14920 1/20 0.50
▸ NAPRT Q6XQN6 1/20 0.50
▸ SLC6A2 P23975 1/20 0.50
▸ SLC6A3 Q01959 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL9421536 0.97 LMNA (0.76) LMNAF2TSHRALDH1A1TDP1
SCHEMBL5173689 0.95 LMNA (0.80) LMNAF2TSHRALDH1A1TDP1
SCHEMBL28496662 0.93 LMNA (0.70) LMNAF2TSHRALDH1A1TDP1
SCHEMBL9438166 0.92 LMNA (0.76) LMNAF2TSHRALDH1A1TDP1
Benzoyl Peroxide SCHEMBL63 0.89 LMNA (1.00) LMNAF2TSHRALDH1A1TDP1
Benzoyl Peroxide SCHEMBL5312311 0.89 LMNA (1.00) LMNAF2TSHRALDH1A1TDP1
Benzoyl Peroxide SCHEMBL2929886 0.89 LMNA (1.00) LMNAF2TSHRALDH1A1TDP1
Benzoyl Peroxide SCHEMBL9407293 0.89 LMNA (1.00) LMNAF2TSHRALDH1A1TDP1
Benzoyl Peroxide SCHEMBL3467853 0.89 LMNA (1.00) LMNAF2TSHRALDH1A1TDP1
SCHEMBL11261669 0.89 LMNA (0.64) LMNAF2TSHRALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240429449-A1 SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING A BENZOYL PEROXIDE BASED COMPOUND ENEVATE CORPORATION 2024-12-26 — — US claimed
CN-115636782-B Synthesis method of polyaryl substituted pyridine 浙江工业大学 2024-07-19 — — CN claimed
US-12021194-B2 Silicon-based energy storage devices with electrolyte containing a benzoyl peroxide based compound ENEVATE CORPORATION (US) 2024-06-25 — — US claimed
US-20230103958-A1 SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING A BENZOYL PEROXIDE BASED COMPOUND ENEVATE CORPORATION 2023-04-06 — — US claimed
CN-115636782-A Synthetic method of polyaryl substituted pyridine 浙江工业大学 2023-01-24 — — CN claimed
US-11462769-B2 Silicon-based energy storage devices with electrolyte containing a benzoyl peroxide based compound ENEVATE CORPORATION (US) 2022-10-04 — — US claimed
US-20210167423-A1 SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING A BENZOYL PEROXIDE BASED COMPOUND ENEVATE CORPORATION 2021-06-03 — — US claimed
US-20110009521-A1 Liquid crystalline epoxy nanicomposite material and application thereof NATIONAL TAIWAN UNIVERSITY (TW) 2011-01-13 — — US claimed
US-12252568-B2 Silicone copolymer surface additive XEROX CORPORATION (US) 2025-03-18 — — US disclosed
US-20240429449-A1 SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE CONTAINING A BENZOYL PEROXIDE BASED COMPOUND ENEVATE CORPORATION 2024-12-26 — — US disclosed
CN-114555570-B Oral complement factor D inhibitors 拜奥克里斯特制药公司 2024-09-13 — — CN disclosed
CN-113508118-B Fused tricyclic compounds useful as anticancer agents 阿斯利康(瑞典)有限公司 2024-07-19 — — CN disclosed
CN-115636782-B Synthesis method of polyaryl substituted pyridine 浙江工业大学 2024-07-19 — — CN disclosed
US-12021194-B2 Silicon-based energy storage devices with electrolyte containing a benzoyl peroxide based compound ENEVATE CORPORATION (US) 2024-06-25 — — US disclosed
EP-2984087-A1 AZITHROMYCIN ANTIMICROBIAL DERIVATIVES WITH NON-ANTIBIOTIC PHARMACEUTICAL EFFECT Probiotic Pharmaceuticals APS (DK) 2016-02-17 — — EP disclosed
US-20160031925-A1 AZITHROMYCIN ANTIMICROBIAL DERIVATIVES WITH NON-ANTIBIOTIC PHARMACEUTICAL EFFECT PROBIOTIC PHARMACEUTICALS APS (DK) 2016-02-04 — — US disclosed
WO-2014166503-A1 AZITHROMYCIN ANTIMICROBIAL DERIVATIVES WITH NON-ANTIBIOTIC PHARMACEUTICAL EFFECT PROBIOTIC PHARMACEUTICALS APS (DK) 2014-10-16 — — WO disclosed
US-8623855-B2 Azetidinone compounds and medical use thereof ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2014-01-07 — — US disclosed
US-20120208994-A1 AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2012-08-16 — — US disclosed
US-5904984-A WITHSTANDS HIGH TEMPERATURE, HIGH STRESS SIEMENS WESTINGHOUSE POWER CORPORATION (US) 1999-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160031925-A1 AZITHROMYCIN ANTIMICROBIAL DERIVATIVES WITH NON-ANTIBIOTIC PHARMACEUTICAL EFFECT CFTR, AZI2, PTPN5 LMNA 4738/4885F2 4875/4885TSHR 3426/4885
US-20110009521-A1 Liquid crystalline epoxy nanicomposite material and application thereof NUP205, CNP, NOS2 LMNA 83/4885F2 4278/4885TSHR 4599/4885
US-20120208994-A1 AZETIDINONE COMPOUNDS AND MEDICAL USE THEREOF CYP46A1, APOB, CETP LMNA 1008/4885F2 385/4885TSHR 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.